25
Participants
Start Date
October 10, 2023
Primary Completion Date
November 7, 2024
Study Completion Date
June 13, 2025
AFM13
anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion
AB-101
NK cell therapy, intravenous infusion
Cyclophosphamide
Lymphodepleting chemotherapy, intravenous infusion
Fludarabine
Lymphodepleting chemotherapy, intravenous infusion
Interleukin-2
Immune cytokine, subcutaneously
Memorial Sloan Kettering Cancer Center, New York
University of Pennsylvania, Abramson Cancer Center, Philadelphia
Fox Chase Cancer Center, Philadelphia
UNC Immunotherapy Team, University of North Carolina at Chapel Hill, Chapel Hill
O'Neal Comprehensive Cancer Center at UAB, Birmingham
Norton Cancer Institute, Louisville
Cleveland Clinic, Cleveland
Karmanos Cancer Institute, Detroit
Masonic Cancer Center, University of Minnesota, Minneapolis
Washington University School of Medicine, St Louis
Sarah Cannon Research Institute, Denver
City of Hope National Medical Center, Duarte
UC Irvine Health, Orange
Beth Israel Deaconess Medical, Boston
John Theurer Cancer Center, Hackensack
Lead Sponsor
Collaborators (1)
Artiva Biotherapeutics, Inc.
INDUSTRY
Affimed GmbH
INDUSTRY